Spondyloarthritis & psoriatic arthritis
Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study
Authors' conclusion
IXE patients had significantly greater odds of achieving cDAPSA remission and VLDA, plus greater pain reduction versus the pooled IL-12/23i and IL-23i group, with significant improvements in BSA versus TNFi. Treatment persistence was similar among all b/tsDMARDs.
Study context
- Population
- Patients with PsA initiating ixekizumab (IXE) or other b/tsDMARDs in a real-world multinational cohortmultinational cohort
- Participants
- 1,192 patients
- Exposure
- IXE vs other b/tsDMARDs
- Outcome
- Effectiveness (cDAPSA, BSA, pain) and persistence
- Follow-up
- 12 months
Methodological detailsprespecified interim analysis of PRO-SPIRIT, multinational, frequentist model averaging, multiple imputation for missing data
- Prespecified interim analysis of PRO-SPIRIT
- Multinational
- Frequentist model averaging
- Multiple imputation for missing data
Main finding
As reported in the abstract
Effectiveness, IXE vs other b/tsDMARDs · month 12
IXE
18.8%
Odds ratio (95% CI)
IXEvs IL-12/23i & IL-23icDAPSA remission
2.0(1.2–6.0)
IXEvs IL-12/23i & IL-23iVLDA
2.5(1.1–13.6)
Least squares mean (LSM)
- IXE vs IL-12/23i & IL-23i · pain reduction (greater with IXE)
- −7.3 (95% CI −13.2 to −0.7)
- IXE vs tumour necrosis factor inhibitors (TNFi) · body surface area (BSA) improvement (greater with IXE)
- −0.9 (95% CI −1.4 to −0.1)
Observational data: associations, not effects.
Original publication
Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study. RMD Open. Published 2 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →